内镜下经鼻蝶入路治疗促甲状腺激素分泌型垂体腺瘤:单中心49例经验与临床结局
单中心回顾性分析49例促甲状腺激素分泌型垂体腺瘤患者接受内镜下经鼻蝶手术的资料。平均肿瘤大小21.12 mm,33例(67.34%)早期缓解,44例(89.79%)随访>3个月甲状腺功能正常;>2 cm肿瘤及海绵窦侵犯对切除率的负面影响有统计学意义(P < 0.001)。
要点
- 内镜下经鼻蝶手术是促甲状腺激素分泌型垂体腺瘤的一线治疗,应在三级中心进行。
- 全切除是目标,早期诊断对手术成功至关重要。
- 肿瘤>2 cm和海绵窦侵犯对切除率的负面影响有统计学意义(P < 0.001)。
核心结论
- 内镜下经鼻蝶手术是促甲状腺激素分泌型垂体腺瘤的一线治疗,应在三级中心进行。
- 全切除是目标,早期诊断对手术成功至关重要。
研究设计与样本
- 单中心研究,回顾性分析49例诊断为促甲状腺激素分泌型垂体腺瘤患者的临床、影像、手术及内分泌资料。
主要发现
- 平均肿瘤大小21.12 mm(微腺瘤6例,大腺瘤41例,巨大腺瘤2例)。
- 海绵窦侵犯12例(24.48%),肿瘤质地坚韧23例(46.93%),多激素分泌9例(生长激素+促甲状腺激素5例,生长激素+催乳素+促甲状腺激素4例)。
- 平均随访51.73个月;全切除32例(65.30%),近全切除14例(28.57%),次全切除3例(6.12%)。
- 早期缓解33例(67.34%),随访>3个月甲状腺功能正常44例(89.79%)。
- 并发症:新发垂体功能减退4例,永久性尿崩症3例,甲状腺危象1例,脑脊液漏1例。
关键数值与推荐
- 肿瘤>2 cm和海绵窦侵犯对切除率的负面影响有统计学意义(P < 0.001)。
- 坚韧肿瘤患者中14例有抗甲状腺药物使用史,抗甲状腺药物与肿瘤坚韧度之间无统计学显著相关性。
临床怎么用
- 原文结论指出内镜下经鼻蝶手术是促甲状腺激素分泌型垂体腺瘤的一线治疗,应在三级中心进行,全切除是目标,早期诊断对手术成功至关重要。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To analyze surgical outcomes and tumor characteristics of 49 patients with thyrotropin-secreting pituitary adenoma, a rare functional pituitary adenoma subtype with challenging surgery, who underwent endoscopic endonasal transsphenoidal surgery. METHODS: In this single-center study, clinical, radiological, surgical, and endocrinological data of 49 patients diagnosed with thyrotropin-secreting pituitary adenoma were retrospectively reviewed. RESULTS: Mean tumor size was 21.12 mm (6 microadenomas, 41 macroadenomas, 2 giant adenomas). Cavernous sinus invasion was present in 12 (24.48%) patients. Tumor consistency was firm in 23 (46.93%) patients. Plurihormonal secretion characteristics were present in 9 patients (5 growth hormone + thyrotropin and 4 growth hormone + prolactin + thyrotropin). Mean follow-up duration was 51.73 months. Of the cases with firm tumors, 14 patients had a history of antithyroid drug use; there was no statistically significant correlation between the antithyroid medication and the firmness of the tumor. Gross total resection was achieved in 32 (65.30%) cases, near-total resection was achieved in 14 (28.57%) cases, and subtotal resection was achieved in 3 (6.12%) cases. The analysis showed that the negative effect of >2 cm tumor size and cavernous sinus invasion on resection rate was statistically significant (P < 0.001). Although early remission was achieved in 33 (67.34%) patients, 44 (89.79%) patients were in euthyroid state at >3 months' follow-up. Complications were 4 new-onset pituitary deficiencies, 3 cases of permanent diabetes insipidus, 1 thyrotoxic crisis, and 1 cerebrospinal fluid leak. CONCLUSIONS: Endoscopic endonasal transsphenoidal surgery is the first-line treatment in thyrotropin-secreting pituitary adenoma and should be performed in a tertiary center. Gross total resection is the goal, and early diagnosis is essential for surgical success.
引用
- Sen HE, Ceylan EC, Atayev S, et al. The Endoscopic Endonasal Transsphenoidal Approach for Thyrotropin-Secreting Pituitary Adenomas: Single-Center Experience and Clinical Outcomes of 49 Patients. World Neurosurg. 2022. PMID: 36096394. doi:10.1016/j.wneu.2022.09.027
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。